Reports record-high revenues since inceptionMONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty ...

Q4 2024 Earnings Call Transcript March 20, 2025 Autolus Therapeutics plc beats earnings expectations. Reported EPS is $-0.09, ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Clinical hold lifted for late stage cadisegliatin program for diabetesCATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

Wexford-based biopharmaceutical company Coeptis Inc. announced the formation of GEAR Therapeutics, a majority-owned ...

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...

We assign TG Therapeutics a buy rating with a 12-month price target of $44 seeing a material impact of interim data readout through Briumvi SC as well as continued sales performance of Briumvi.

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell ...